EXHIBIT 99.2
Published on January 7, 2026
Exhibit 99.2
Tumor HI EAP Patient Profiles
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8# | Patient 9 | |
| Gender (M/F) / Age (Years) | M / 55 | F / 50 | F / 50 | F / 43 | M / 74 | M / 62 | M / 74 | M / 53 | M / 24 |
| Diagnosis | Metastatic Insulinoma | Metastatic Insulinoma | Neuroendocrine Carcinoma of the Cervix | Metastatic Insulinoma | Metastatic Insulinoma | Metastatic Insulinoma |
Metastatic Insulinoma |
Metastatic Proinsulinoma | Metastatic Insulinoma |
| # of Anti-hypoglycemic therapies at enrollment | 4 | 3 | 3 | 4 | 4 | 3 | 5 | 2 | 4 |
| Glucose Infusion Rate (GIR, mg/kg/min) at ersodetug initiation | 6.0 |
7.0 (home TPN) |
5.1 | 6.2 | 4.9 | n/a (ambulatory) | 5.6 | Unknown amount | 3.1 |
| Ersodetug Dose Regimen (dose/frequency) | 6-9 mg/kg every 1-4 weeks | 6-9 mg/kg every 1-2 weeks | 9 mg/kg, every 1-2 weeks | 9-12 mg/kg every 1-2 weeks | 9 mg/kg every 1-3 weeks | 9 mg/kg every 1-2 weeks | 6-9 mg/kg every 1-2 weeks | 9 mg/kg every 1-2 weeks | 9 mg/kg every 1-3 weeks |
| Percent Reduction in GIR by 8 weeks of Ersodetug treatment (duration of Phase 3 upLIFT study) | >50%, then 100% by 9 weeks | <50% | 100% | 100% | 100% | n/a | 100% | Unknown amount | 100% |
| Time to IV Glucose discontinuation (days) | 74 | 139 (achieved 50% reduction) |
4 | 5 | 2 | n/a | 3 | n/a | 42 |
| Length of Hospitalization prior to ersodetug (days) | 28 | n/a (ambulatory) | 15 | 49 | 34 | n/a (ambulatory) | 4 | Unknown duration | 16 |
| # of Hospitalized Days in the 30-day period following ersodetug initiation | 30 | 0 | 7 | 8 | 8 | 0 | 16 | 30 | 1 |
| Baseline ECOG * | 3 | 2 | 3 | 3 | 3 | 1 | 1 | 3 | 1 |
| ECOG, Month 3 on ersodetug | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 5 | 0 |
| Total Duration of ersodetug therapy (months) | 13 | 5 | 5 | 14 | 22 (ongoing) | 18 (ongoing) | 6 | 1.5 | 10 |
| Overall Survival (months) | 14 | 5 | 5 | 14 | 22 (living) | 18 (living) | 6 | 1.5 | 10 |
# Patient was critically ill when treatment commenced and died of sepsis prior to determination of whether there was a therapeutic effect
*Eastern Cooperative Oncology Group (ECOG) Performance Status is a standardized measure of functional status ranging from 0 (fully active) to 5 (death), with increasing scores indicating greater disability and reduced ability to perform daily activities